Hochschulschrift
Impact of BET bromodomain inhibition on KRAS-mutated non-small cell lung cancer
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
Berlin, Humboldt Universität zu Berlin, Dissertation, 2016
- Schlagwort
-
Krebs
Onkologie
- Ereignis
-
Veröffentlichung
- (wo)
-
Berlin
- (wer)
-
Lebenswissenschaftliche Fakultät
- (wann)
-
2016
- Urheber
- Beteiligte Personen und Organisationen
-
Ehrenhofer-Murray, Ann
Haendler, Bernhard
Ocker, Matthias
- URN
-
urn:nbn:de:kobv:11-100243276
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
25.03.2025, 13:46 MEZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Objekttyp
- Hochschulschrift
Beteiligte
- Klingbeil, Olaf
- Ehrenhofer-Murray, Ann
- Haendler, Bernhard
- Ocker, Matthias
- Lebenswissenschaftliche Fakultät
Entstanden
- 2016
Ähnliche Objekte (12)
Sotorasib in KRAS G12C-mutated non-small cell lung cancer: A multicenter real-world experience from the compassionate use program in Germany
Frequency and clinicopathologic correlates of KRAS amplification in Non-small cell lung carcinoma
First-line treatment of EGFR-mutated nonsmall cell lung cancer : critical review on study methodology
The Role of DREAM/MMB-mediated mitotic gene expression downstream of mutated K-Ras in lung cancer
Non-small cell lung cancer treatment
Non-small cell lung cancer treatment
Non-small cell lung cancer treatment
Afatinib as first-line treatment in patients with EGFR-mutated non-small cell lung cancer in routine clinical practice
Lasting response by vertical inhibition with cetuximab and trametinib in \(\it KRAS\)-mutated colorectal cancer patient-derived xenografts
Inhibition of LSD1 in non-small cell lung cancer - in vitro and in vivo
Inhibition of MCL-1 blocks the development of KRAS-driven adenocarcinoma of the lung
CRISPR/Cas9-Mediated Knock-Out of KrasG12D Mutated Pancreatic Cancer Cell Lines
Sotorasib in KRAS G12C-mutated non-small cell lung cancer: A multicenter real-world experience from the compassionate use program in Germany
Frequency and clinicopathologic correlates of KRAS amplification in Non-small cell lung carcinoma
First-line treatment of EGFR-mutated nonsmall cell lung cancer : critical review on study methodology
The Role of DREAM/MMB-mediated mitotic gene expression downstream of mutated K-Ras in lung cancer
Non-small cell lung cancer treatment
Non-small cell lung cancer treatment
Non-small cell lung cancer treatment
Afatinib as first-line treatment in patients with EGFR-mutated non-small cell lung cancer in routine clinical practice
Lasting response by vertical inhibition with cetuximab and trametinib in \(\it KRAS\)-mutated colorectal cancer patient-derived xenografts
Inhibition of LSD1 in non-small cell lung cancer - in vitro and in vivo
Inhibition of MCL-1 blocks the development of KRAS-driven adenocarcinoma of the lung
CRISPR/Cas9-Mediated Knock-Out of KrasG12D Mutated Pancreatic Cancer Cell Lines
Sotorasib in KRAS G12C-mutated non-small cell lung cancer: A multicenter real-world experience from the compassionate use program in Germany
Frequency and clinicopathologic correlates of KRAS amplification in Non-small cell lung carcinoma
First-line treatment of EGFR-mutated nonsmall cell lung cancer : critical review on study methodology
The Role of DREAM/MMB-mediated mitotic gene expression downstream of mutated K-Ras in lung cancer
Non-small cell lung cancer treatment
Non-small cell lung cancer treatment
Non-small cell lung cancer treatment
Afatinib as first-line treatment in patients with EGFR-mutated non-small cell lung cancer in routine clinical practice
Lasting response by vertical inhibition with cetuximab and trametinib in \(\it KRAS\)-mutated colorectal cancer patient-derived xenografts
Inhibition of LSD1 in non-small cell lung cancer - in vitro and in vivo
Inhibition of MCL-1 blocks the development of KRAS-driven adenocarcinoma of the lung